Vaccine based on TGEV for protection of canines against canine coronavirus
AssigneePfizer Inc.
InventorsDale Bordt, Hans Draayer
Life of this patent
Estimating the term…
Abstract
A method for preventing canine coronavirus in dogs is disclosed which comprises administering to a dog a live or inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine). An inactivated vaccine composition for use in such a method and a process for the manufacture of the inactivated vaccine composition are described.
Claims6
A vaccine composition suitable for administration to a canine, said composition comprising inactivated transmissible gastroenteritis virus of swine (TGEV).
A process for manufacturing an inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine), which process comprises:
- (a) passing an isolate of TGE virus in cells of porcine and/or feline origin at a virus to cell ratio 2 of 1:1 to 1:10,000 to obtain an attenuated live TGE virus;
- (b) propagating the live TGE virus by cell culture in mammalian cells;
- (c) harvesting viral fluids so produced;
- and
- (d) inactivating the said viral fluids with a viral inactivating agent.
Dependencies are inferred from the claim text.